Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pseudoginsenoside F11
- Development stage
- Preclinical
- Lead developer
- Nankai University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pseudoginsenoside F11 (PF11) is a natural ocotillol-type saponin primarily derived from *Panax quinquefolius* (American ginseng). It has been identified as a potent inhibitor of phosphoribosyl pyrophosphate synthetase 2 (PRPS2) transcription, a key driver of hyperactive de novo nucleotide synthesis in metastatic cancers. Mechanistically, PF11 directly binds to the transcription factor YBX1, enhancing its affinity for the PRPS2 promoter. This binding enables YBX1 to compete with and displace the transcriptional activator c-Myc, subsequently recruiting the NuRD corepressor complex to repress PRPS2 expression. This pathway effectively attenuates the stemness and pulmonary metastasis of triple-negative breast cancer (TNBC). Beyond oncology, PF11 has been extensively studied for its neuroprotective effects, demonstrating potential in preclinical models of Alzheimer's disease, ischemic stroke, and drug-induced cognitive impairment through antioxidant and anti-inflammatory mechanisms.
- Other names
- Pseudoginsenoside F11
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)YBX1 (Y-box-binding protein 1)PRPS2PPARG (Peroxisome proliferator-activated receptor gamma)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on pseudoginsenoside F11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pseudoginsenoside F11.